News ArticleGlaxoSmithKline India Achieves 21% Revenue Growth in Q2 FY27 with Innovation-Driven Portfolio Expansion
Company reports ₹1180 crore quarterly revenue, maintains 25% market share, and records 33% PAT growth despite margin pressures
GlaxoSmithKline Pharmaceuticals Limited posted a revenue growth of 21% in Q2 FY27, driven by execution excellence and a growing innovation portfolio accounting for 7% of total sales. The company maintains its leadership with a 25% share in the representative market and continues transformation powered by oncology, adult vaccines, and respiratory segments. EBITDA stood at ₹400 crore with a 34% margin, and PAT rose 33% with a margin improvement, despite gross margin pressures from currency and input costs.
GlaxoSmithKline Pharmaceuticals Limited
Investor Presentation
GlaxoSmithKline Pharmaceuticals Limited reported a 21% revenue increase to ₹1180 crore in Q2 FY27, driven by strong sales execution and a rising contribution from its innovation portfolio which grew to 7% of total sales. The company sustained market leadership with a 25% share in its representative market amid competitive industry growth.
The company achieved ₹400 crore in EBITDA for the quarter with a margin of 34%, a slight decline due to gross margin pressures from currency depreciation and higher input costs, partially offset by price increases and cost efficiencies.
Profit after tax (PAT) before exceptional items amounted to ₹335 crore, representing a 33% growth with a margin of 29%, helped in part by interest from income tax refunds.
GSK India’s innovation portfolio includes oncology products (Jemperli, Zejulo), new respiratory treatments (Nucala, Trelegy), and adult vaccines (Shingrix), which collectively supported growth and represent 7% of total sales compared to 3% in the previous year.
Market leadership was maintained with 25% share in the company’s representative market, supported by strong performance in general medicines and vaccines portfolios, and competitive growth across metro and specialty segments.
The Indian Pharmaceutical Market grew by 14.7% in Jul-Sep 2026, with chronic therapy segments growing faster than acute; GSK’s representative market grew by 11%, outperforming overall market growth.
Highlights
- Q2 FY27 revenue of ₹1180 crore with 21% growth year-over-year
- EBITDA at ₹400 crore with 34% margin; margin declined by 50 basis points
- PAT before exceptional items increased by 33% to ₹335 crore with 29% margin
- Innovation portfolio sales doubled to 7% of total sales from 3% last year
- GSK maintains 25% share in representative market alongside leading positions in vaccines and general medicines
- Shingrix adult vaccine sales doubled, targeting adult immunization market growth
Key Data Snapshot
What happened
- GlaxoSmithKline Pharmaceuticals Limited reported robust growth in Q2 FY27 driven by portfolio transformation and execution excellence.
- The company’s revenue rose 21% to ₹1180 crore with a notable increase in innovation portfolio share to 7%.
- EBITDA was ₹400 crore with a 34% margin, slightly impacted by higher costs and currency depreciation.
- PAT increased 33% to ₹335 crore, aided by income tax refunds.
- GSK sustained a 25% share in its representative market, outperforming overall pharmaceutical market growth.
- Key therapeutic areas contributing to growth included oncology, adult vaccines, and respiratory segments.
Key details
- The innovation portfolio includes products such as Jemperli and Zejulo (oncology), Nucala and Trelegy (respiratory), and adult vaccine Shingrix.
- General medicines growth was led by brands such as Augmentin, Calpol, Neosporin, and T-Bact.
- Shingrix vaccine sales doubled over the prior year, emphasizing development in adult immunization.
- GSK’s vaccine portfolio holds a 26% market share in the representative market, confirming leadership.
- Margins were impacted by currency depreciation and higher input costs but partially offset by price increases and cost control measures.
Financial performance
- Revenue for H1 FY27 reached ₹2104 crore, up 18% year-over-year.
- EBITDA for H1 FY27 was ₹693 crore with a 33% margin, showing margin improvement.
- PAT for H1 FY27 rose to ₹588 crore with a 28% margin, up 29% year-over-year.
- EPS for Q2 FY27 was 19.76, reflecting a 32% increase from previous year.
- SG&A expenses as a percentage of sales reduced by 1% due to cost efficiencies.
Highlights
- Q2 FY27 revenue of ₹1180 crore with 21% growth year-over-year
- EBITDA at ₹400 crore with 34% margin; margin declined by 50 basis points
- PAT before exceptional items increased by 33% to ₹335 crore with 29% margin
- Innovation portfolio sales doubled to 7% of total sales from 3% last year
- GSK maintains 25% share in representative market alongside leading positions in vaccines and general medicines
- Shingrix adult vaccine sales doubled, targeting adult immunization market growth
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Multi Commodity Exchange of India Ltd Reports Nearly 100% Increase in Total Income for H1 FY27 with ₹1,603 Crore
Multi Commodity Exchange of India Ltd (MCX) reported total income of ₹1,603 crore for the half year ended September 30, 2026, nearly doubling the ₹807 crore recorded in the same period last year. Profit after tax reached ₹868 crore, showcasing substantial financial growth.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 mn Revenue in Q2 FY27 with 29% YoY Growth Bolstered by India Formulations
Zydus Lifesciences Limited recorded a 29% year-on-year increase in revenues to Rs. 79,096 million during the second quarter of fiscal year 2027, driven primarily by robust growth in their India branded formulations and North America markets.
Read Full Story
ITC Limited Announces Participation in Major Investor Conferences in November 2026
ITC Limited announced that its representatives will participate in two key investor conferences in November 2026, including the 29th CITIC CLSA India Forum in Mumbai and Morgan Stanley's 25th Annual Asia Pacific Summit in Singapore.
Read Full Story
